FDA Releases FY25 Sampling Results on Economically Motivated Adulteration in Honey

The U.S. Food and Drug Administration has released its FY2025 sampling results focused on economically motivated adulteration (EMA) in honey.

The sampling program is part of FDA’s ongoing efforts to detect food fraud and ensure the authenticity of products in the marketplace. Honey has historically been identified as a higher-risk commodity for adulteration due to economic incentives and global supply chain complexity.

Key Takeaways from FDA Sampling

FDA’s sampling initiative evaluated honey products for potential adulteration, including the presence of undeclared sweeteners or other substances that may compromise product integrity.

The Agency uses this type of targeted surveillance to:

• Identify potential food fraud risks
• Monitor product authenticity in the marketplace
• Inform future enforcement and regulatory priorities

Why Honey Remains a Focus Area

Economically motivated adulteration occurs when substances are intentionally added or substituted for economic gain. In the case of honey, this may involve dilution with lower-cost sweeteners or misrepresentation of origin.

Global sourcing and complex supply chains can increase vulnerability to these types of risks.

What This Means for Industry

Companies sourcing or distributing honey and other high-risk ingredients should continue to:

• Evaluate supplier verification programs
• Assess vulnerability to food fraud risks
• Implement appropriate testing and authentication strategies
• Strengthen supply chain transparency

FDA’s continued focus on EMA signals the importance of proactive risk management in food safety programs.

EAS Perspective

• On-Demand Webinar: Food Fraud Mitigations and Testing
• Food Fraud Services Overview: 1-page Information sheet